Principal Investigator
Richa Dawar
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240228
Clinical Trial Summary
A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Pembrolizumab Compared with Docetaxel in Patients with Non-Small-Cell Lung Cancer after First Progression While on Front-Line Pembrolizumab-based Maintenance (VIRO-25 Study)
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
305-243-2647